Drug intelligence / Profile preview

Lacrisomes

Development stage: Preclinical
Modality: Drug Delivery Systems
Administration: Ophthalmic

Overview

Lacrisomes are a collagen-based drug delivery system designed for ophthalmic use, specifically for the treatment of dry eyes. They consist of collagen pieces chemically altered with the inclusion of a lipid (such as cetyl alcohol) and suspended in a viscous vehicle. This formulation allows for simplified application into the lower forniceal space, aiming to provide high and sustained levels of drugs and/or lubricants to the cornea, offering a soothing effect and prolonged comfort for patients. They are a modification of Collasomes, incorporating a lipid for enhanced efficacy in dry eye conditions.

Beyond the preview

Go deeper on Lacrisomes.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lacrisomes.

Explore the full profile